NCT07007559 2026-04-13
ASPEN-09-03
ALX Oncology Inc.
Phase 2 Recruiting
Clinical Trials
11 trialsNCT07203729 2026-03-16
The Efficacy and Safety of Trastuzumab Rezetecan (SHR-A1811) in HER2-Low Unresectable/Metastatic Breast Cancer Patients With Visceral Crisis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT06875128 2026-03-13
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Delcath Systems Inc.
Phase 2 Recruiting
NCT06690840 2026-01-05
AZALEA
European Institute of Oncology
Phase 2 Recruiting
NCT07088263 2025-12-11
Adaptive Chemotherapy for the Treatment of Advanced Breast Cancer
Sun Yat-sen University
Phase 3 Recruiting
NCT06081959 2025-12-05
Study of SKB264 for Locally Advanced, Recurrent or Metastatic HR+/HER2- Breast Cancer
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Phase 3 Recruiting
NCT06079983 2025-09-12
JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 3 Recruiting
NCT06383767 2025-06-19
A Phase III Study of ESG401 for Locally Advanced or Metastatic HR+/HER2- Breast Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06143553 2024-11-29
Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer
Shanghai Yizhong Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT06202261 2024-03-12
A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2 Recruiting
NCT06268652 2024-02-20
Patient Derived Organoid-guided Personalized Treatment Versus Treatment of Physician's Choice in Breast Cancer
Sun Yat-sen University
Phase 3 Recruiting